MRSO, Inc. (5619) AI Stock Analysis

• Market Cap: ¥3.73B
• Dividend Yield: N/A
• Average Volume (3M): 2.95K
• Price to Earnings (P/E): 889.3
• Beta (1Y): 0.02
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 21
• Sector: Services
• Sector Strength: N/A
• Industry: Software - Application
• EPS (TTM): -5.41
• Shares Outstanding: 3,552,750
• 10 Day Avg. Volume: 2,170
• 30 Day Avg. Volume: 2,953
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,130.00
• Price Target Upside: 6.10% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: ¥1,041.00 ▼(-2.25% Downside)

The overall stock score is primarily impacted by financial performance challenges, including declining revenue and negative cash flow. Technical analysis shows mixed signals, while the valuation suggests overvaluation with a high P/E ratio. The absence of earnings call and corporate events data limits further insights.

MRSO, Inc. Business Overview & Revenue Model

Company Description

MRSO, Inc. (5619) is a technology-driven company specializing in the development and manufacturing of innovative solutions within the healthcare sector. The company focuses on creating advanced medical devices and software solutions designed to improve patient outcomes and streamline healthcare operations. MRSO, Inc. operates in various segments, including diagnostics, patient monitoring, and healthcare information management, providing a comprehensive suite of products and services aimed at healthcare providers and institutions.

How the Company Makes Money

MRSO, Inc. generates revenue primarily through the sale of its medical devices and software solutions to healthcare providers, hospitals, and clinics. The company employs a direct sales model complemented by partnerships with distributors to expand its market reach. Key revenue streams include product sales, recurring revenue from software subscriptions and service contracts, and consulting services for healthcare systems. Additionally, MRSO, Inc. benefits from strategic partnerships with other technology firms and healthcare organizations, which enhance its product offerings and market position, contributing significantly to its earnings.

MRSO, Inc. Financial Statement Overview

Summary

MRSO, Inc. faces significant financial challenges, with declining revenue and profitability. The income statement shows a reduced net profit margin and a significant drop in revenue. Although the balance sheet is strong with minimal leverage, the cash flow situation is concerning due to negative free cash flow and reduced cash generation from operations.

Income Statement

MRSO, Inc. has experienced a significant decline in revenue and profitability over the past year. The gross profit margin remains strong at approximately 77.2% for 2024, but the net profit margin has decreased to 7.6% from 21.4% in 2023, indicating reduced profitability. Revenue has decreased by 26.3% from 2023 to 2024, highlighting challenges in maintaining sales growth. EBIT and EBITDA margins have also declined, reflecting operational inefficiencies.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.003, indicating minimal leverage and financial risk. The equity ratio is high at 89.6%, showcasing strong equity financing. However, the return on equity has fallen to 5.0% in 2024 from 20.6% in 2023, suggesting reduced profitability on shareholder investments.

Cash Flow

MRSO, Inc. faces cash flow challenges, with a negative free cash flow of -77.6 million in 2024 compared to a positive 43.1 million in 2023. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to net income. The free cash flow to net income ratio is also negative, reflecting difficulties in generating cash from operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.33B	1.81B	2.25B	1.74B
Gross Profit	1.03B	1.45B	1.79B	1.35B
EBITDA	163.77M	612.32M	1.01B	914.67M
Net Income	101.00M	387.55M	653.83M	650.88M
Balance Sheet
Total Assets	2.26B	2.25B	2.08B	1.70B
Cash, Cash Equivalents and Short-Term Investments	1.81B	1.93B	1.74B	1.42B
Total Debt	7.37M	15.36M	23.35M	31.34M
Total Liabilities	234.45M	373.01M	744.00M	655.32M
Stockholders Equity	2.02B	1.88B	1.34B	1.04B
Cash Flow
Free Cash Flow	-77.63M	43.06M	695.05M	1.10B
Operating Cash Flow	-77.63M	48.28M	696.31M	1.11B
Investing Cash Flow	-59.69M	-8.31M	-1.43M	-12.95M
Financing Cash Flow	22.89M	144.36M	-367.99M	-7.99M

MRSO, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1065.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:5619, the sentiment is Negative. The current price of 1065 is below the 20-day moving average (MA) of 1095.40, above the 50-day MA of 1051.64, and above the 200-day MA of 1001.17, indicating a neutral trend. The MACD of 1.61 indicates Positive momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 24.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:5619.

MRSO, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3744	76 Outperform	¥4.38B	9.49		1.39%	-7.06%	147.27%
4447	72 Outperform	¥3.93B	20.26		1.63%	42.88%	-5.21%
6633	67 Neutral	¥3.67B	13.37		2.60%	21.10%	―
3710	62 Neutral	¥3.08B	28.19		1.00%	-6.71%	―
3909	60 Neutral	¥4.39B	12.31		―	-8.20%	―
Sector *	56 Neutral	$13.44B	18.26	10.03%	0.94%	7.13%	-12.93%
5619	49 Neutral	¥3.73B	889.34		―	―	―